EGFR and neuroendocrine carcinoma: Vorolanib (CM082) 20 (Fig. 6) is an oral VEGFR and PDGFR inhibitor.81 A phase I study (22 patients) exhibited promising results for the combination of vorolanib with everolimus 21 towards renal and neuroendocrine cancers.82 It has also mentioned that vorolanib enhances the antiproliferation and apoptosis properties of gefitinib (Iressa) 22 (EGFR: epidermal growth factor receptor, inhibitor) towards NSCLC cell lines (HCC827 and H3255).